<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34529228</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7373</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>154</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neuro-oncology</Title>
          <ISOAbbreviation>J Neurooncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.</ArticleTitle>
        <Pagination>
          <StartPage>265</StartPage>
          <EndPage>274</EndPage>
          <MedlinePgn>265-274</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11060-021-03846-z</ELocationID>
        <Abstract>
          <AbstractText>The leading cause of early death in patients with neurofibromatosis type 1 (NF1) is malignant peripheral nerve sheath tumor (MPNST). The principles of management include early diagnosis, surgical clearance and close monitoring for tumor recurrence. Current methods for diagnosis, detection of residual disease and monitoring tumor burden are inadequate, as clinical and radiological features are non-specific for malignancy in patients with multiple tumors and lack the sensitivity to identify early evidence of malignant transformation or tumor recurrence. Circulating tumor DNA (ctDNA) is a promising tool in cancer management and has the potential to improve the care of patients with NF1. In the following article we summarise the current understanding of the genomic landscape of MPNST, report on the previous literature of ctDNA in MPNST and outline the potential clinical applications for ctDNA in NF1 associated MPNST. Finally, we describe our prospective cohort study protocol investigating the utility of using ctDNA as an early diagnostic tool for MPNSTs in NF1 patients.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jones</LastName>
            <ForeName>Jordan</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-6833-956X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Melbourne, Melbourne, VIC, Australia. jordan.jones@mh.org.au.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, VIC, 3050, Australia. jordan.jones@mh.org.au.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cain</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, VIC, 3050, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pesic-Smith</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, VIC, 3050, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choong</LastName>
            <ForeName>Peter F M</ForeName>
            <Initials>PFM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Melbourne, Melbourne, VIC, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Orthopaedics, St Vincent's Hospital, Melbourne, VIC, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bone and Soft Tissue Sarcoma Service, Perter MacCallum Cancer Centre, Melbourne, VIC, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morokoff</LastName>
            <ForeName>Andrew P</ForeName>
            <Initials>AP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Melbourne, Melbourne, VIC, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, VIC, 3050, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Drummond</LastName>
            <ForeName>Kate J</ForeName>
            <Initials>KJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Melbourne, Melbourne, VIC, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, VIC, 3050, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dabscheck</LastName>
            <ForeName>Gabriel</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Royal Children's Hospital, Melbourne, VIC, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Murdoch Children's Research Institute, Melbourne, VIC, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Neurooncol</MedlineTA>
        <NlmUniqueID>8309335</NlmUniqueID>
        <ISSNLinking>0167-594X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074141">Circulating Tumor DNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000074141" MajorTopicYN="N">Circulating Tumor DNA</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018317" MajorTopicYN="N">Nerve Sheath Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009456" MajorTopicYN="Y">Neurofibromatosis 1</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="Y">Neurofibrosarcoma</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Biomarkers</Keyword>
        <Keyword MajorTopicYN="N">Circulating tumor DNA</Keyword>
        <Keyword MajorTopicYN="N">Liquid biopsy</Keyword>
        <Keyword MajorTopicYN="N">Malignant peripheral nerve sheath tumor</Keyword>
        <Keyword MajorTopicYN="N">Neurofibromatosis type 1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>12</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34529228</ArticleId>
        <ArticleId IdType="doi">10.1007/s11060-021-03846-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s11060-021-03846-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gutmann DH, Wood DL, Collins FS (1991) Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 88:9658–9662. https://doi.org/10.1073/pnas.88.21.9658</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.88.21.9658</ArticleId>
            <ArticleId IdType="pubmed">1946382</ArticleId>
            <ArticleId IdType="pmc">52777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152a:327–332. https://doi.org/10.1002/ajmg.a.33139</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.a.33139</ArticleId>
            <ArticleId IdType="pubmed">20082463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004. https://doi.org/10.1038/nrdp.2017.4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2017.4</ArticleId>
            <ArticleId IdType="pubmed">28230061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, Martin L, Barbarot S, Leheup B, Rodriguez D, Lacombe D, Dollfus H, Pasquier L, Isidor B, Ferkal S, Soulier J, Sanson M, Dieux-Coeslier A, Bièche I, Parfait B, Vidaud M, Wolkenstein P, Upadhyaya M, Vidaud D (2010) NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 31:E1506-1518. https://doi.org/10.1002/humu.21271</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.21271</ArticleId>
            <ArticleId IdType="pubmed">20513137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeClue JE, Cohen BD, Lowy DR (1991) Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci USA 88:9914–9918. https://doi.org/10.1073/pnas.88.22.9914</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.88.22.9914</ArticleId>
            <ArticleId IdType="pubmed">1946460</ArticleId>
            <ArticleId IdType="pmc">52837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zöller M, Rembeck B, Akesson HO, Angervall L (1995) Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg. Sweden Acta Derm Venereol 75:136–140. https://doi.org/10.2340/0001555575136140</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2340/0001555575136140</ArticleId>
            <ArticleId IdType="pubmed">7604643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Airewele GE, Sigurdson AJ, Wiley KJ, Frieden BE, Caldarera LW, Riccardi VM, Lewis RA, Chintagumpala MM, Ater JL, Plon SE, Bondy ML (2001) Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol 20:75–86</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1098-2272(200101)20:1&lt;75::AID-GEPI7&gt;3.0.CO;2-Z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mussi C, Schildhaus H-U, Gronchi A, Wardelmann E, Hohenberger P (2008) Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 14:4550. https://doi.org/10.1158/1078-0432.CCR-08-0086</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-0086</ArticleId>
            <ArticleId IdType="pubmed">18628470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311–314. https://doi.org/10.1136/jmg.39.5.311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.39.5.311</ArticleId>
            <ArticleId IdType="pubmed">1735122</ArticleId>
            <ArticleId IdType="pmc">1735122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandberg A, Stone J (2008) Malignant peripheral nerve sheath tumours. The genetics and molecular biology of neural tumours. Humana Press, Totowa, pp 43–81</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-59745-510-7_2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lothe RA, Smith-Sorensen B, Hektoen M, Stenwig AE, Mandahl N, Saeter G, Mertens F (2001) Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosom Cancer 30:202–206</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1098-2264(2000)9999:9999&lt;::AID-GCC1079&gt;3.0.CO;2-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pemov A, Li H, Presley W, Wallace MR, Miller DT (2020) Genetics of human malignant peripheral nerve sheath tumors. Neurooncol Adv 2:i50–i61. https://doi.org/10.1093/noajnl/vdz049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/noajnl/vdz049</ArticleId>
            <ArticleId IdType="pubmed">32642732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bottillo I, Ahlquist T, Brekke H, Danielsen SA, van den Berg E, Mertens F, Lothe RA, Dallapiccola B (2009) Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol 217:693–701. https://doi.org/10.1002/path.2494</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2494</ArticleId>
            <ArticleId IdType="pubmed">19142971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A, Tap WD, Fletcher JA, Huberman KH, Qin LX, Viale A, Singer S, Zheng D, Berger MF, Chen Y, Antonescu CR, Chi P (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227–1232. https://doi.org/10.1038/ng.3095</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3095</ArticleId>
            <ArticleId IdType="pubmed">25240281</ArticleId>
            <ArticleId IdType="pmc">4249650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korfhage J, Lombard DB (2019) Malignant peripheral nerve sheath tumors: from epigenome to bedside. Mol Cancer Res 17:1417–1428</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-19-0147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleven AH, Al Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovee JV (2016) Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 29:1113. https://doi.org/10.1038/modpathol.2016.103</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2016.103</ArticleId>
            <ArticleId IdType="pubmed">27573709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, Wang Q, Belzberg AJ, Chaichana K, Gallia GL, Gokaslan ZL, Riggins GJ, Wolinksy JP, Wood LD, Montgomery EA, Hruban RH, Kinzler KW, Papadopoulos N, Vogelstein B, Bettegowda C (2014) Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet 46:1170–1172. https://doi.org/10.1038/ng.3116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3116</ArticleId>
            <ArticleId IdType="pubmed">25305755</ArticleId>
            <ArticleId IdType="pmc">4383254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, Clapp W, Bradner J, Vidaud M, Upadhyaya M, Legius E, Cichowski K (2014) PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514:247–251. https://doi.org/10.1038/nature13561</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13561</ArticleId>
            <ArticleId IdType="pubmed">25119042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR (2017) The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep 7:14992. https://doi.org/10.1038/s41598-017-15183-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-15183-1</ArticleId>
            <ArticleId IdType="pubmed">29118384</ArticleId>
            <ArticleId IdType="pmc">5678116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandel P, Metais P (1948) Nuclear acids in human blood plasma. CR Seances Soc Biol Fil 142:241–243</Citation>
        </Reference>
        <Reference>
          <Citation>Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17:223–238. https://doi.org/10.1038/nrc.2017.7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2017.7</ArticleId>
            <ArticleId IdType="pubmed">28233803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev 3:67–71</Citation>
        </Reference>
        <Reference>
          <Citation>Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437. https://doi.org/10.1038/nrc3066</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3066</ArticleId>
            <ArticleId IdType="pubmed">21562580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih LM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. https://doi.org/10.1126/scitranslmed.3007094</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3007094</ArticleId>
            <ArticleId IdType="pubmed">25122639</ArticleId>
            <ArticleId IdType="pmc">4399712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW Jr, Alizadeh AA, Diehn M (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20:548–554. https://doi.org/10.1038/nm.3519</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3519</ArticleId>
            <ArticleId IdType="pubmed">24705333</ArticleId>
            <ArticleId IdType="pmc">4016134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA (2014) Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20:1698–1705. https://doi.org/10.1158/1078-0432.Ccr-13-2482</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.Ccr-13-2482</ArticleId>
            <ArticleId IdType="pubmed">24429876</ArticleId>
            <ArticleId IdType="pmc">3959249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209. https://doi.org/10.1056/NEJMoa1213261</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1213261</ArticleId>
            <ArticleId IdType="pubmed">23484797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112. https://doi.org/10.1038/nature12065</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12065</ArticleId>
            <ArticleId IdType="pubmed">23563269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990. https://doi.org/10.1038/nm.1789</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.1789</ArticleId>
            <ArticleId IdType="pubmed">18670422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aaf6219</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaf6219</ArticleId>
            <ArticleId IdType="pubmed">27384348</ArticleId>
            <ArticleId IdType="pmc">5346159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Bye H, Hubank M, Gevensleben H, Cutts R, Snowdon C, Rea D, Cameron D, Shaaban A, Randle K, Martin S, Wilkinson K, Moretti L, Bliss JM, Ring A (2020) Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol 21:1296–1308. https://doi.org/10.1016/s1470-2045(20)30444-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1470-2045(20)30444-7</ArticleId>
            <ArticleId IdType="pubmed">32919527</ArticleId>
            <ArticleId IdType="pmc">7599319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA (2016) Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34:3375–3382. https://doi.org/10.1200/jco.2016.66.7162</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2016.66.7162</ArticleId>
            <ArticleId IdType="pubmed">27354477</ArticleId>
            <ArticleId IdType="pmc">5035123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815. https://doi.org/10.1038/ncomms11815</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms11815</ArticleId>
            <ArticleId IdType="pubmed">27283993</ArticleId>
            <ArticleId IdType="pmc">4906406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hummel TR, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page GP, Worley PF, Aronow BJ, Schorry EK, Ratner N (2010) Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res 16:5048–5057. https://doi.org/10.1158/1078-0432.Ccr-10-0613</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.Ccr-10-0613</ArticleId>
            <ArticleId IdType="pubmed">20739432</ArticleId>
            <ArticleId IdType="pmc">4837895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson G, Peng P-C, Huang P-Y, Chien H-F, Hua K-T, Kuo M-L, Chen C-T, Lee M-J (2014) Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden. PLoS ONE 9:e115916–e115916. https://doi.org/10.1371/journal.pone.0115916</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0115916</ArticleId>
            <ArticleId IdType="pubmed">25551830</ArticleId>
            <ArticleId IdType="pmc">4281253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolanczyk M, Mautner V, Kossler N, Nguyen R, Kühnisch J, Zemojtel T, Jamsheer A, Wegener E, Thurisch B, Tinschert S, Holtkamp N, Park SJ, Birch P, Kendler D, Harder A, Mundlos S, Kluwe L (2011) MIA is a potential biomarker for tumour load in neurofibromatosis type 1. BMC Med 9:82. https://doi.org/10.1186/1741-7015-9-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1741-7015-9-82</ArticleId>
            <ArticleId IdType="pubmed">21726432</ArticleId>
            <ArticleId IdType="pmc">3224593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SJ, Sawitzki B, Kluwe L, Mautner VF, Holtkamp N, Kurtz A (2013) Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med 11:109. https://doi.org/10.1186/1741-7015-11-109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1741-7015-11-109</ArticleId>
            <ArticleId IdType="pubmed">23618374</ArticleId>
            <ArticleId IdType="pmc">3648455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida Y, Furumura M, Tahira M, Horie T, Yamamoto O (2012) Serum biomarker in neurofibromatosis type 1. J Dermatol Sci 67:155–158. https://doi.org/10.1016/j.jdermsci.2012.04.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2012.04.010</ArticleId>
            <ArticleId IdType="pubmed">22609162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kallionpää RA, Ahramo K, Aaltonen M, Pennanen P, Peltonen J, Peltonen S (2021) Circulating free DNA in the plasma of individuals with neurofibromatosis type 1. Am J Med Genet Part A. https://doi.org/10.1002/ajmg.a.62081</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.a.62081</ArticleId>
            <ArticleId IdType="pubmed">33484105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eastley N, Sommer A, Ottolini B, Neumann R, Luo JL, Hastings RK, McCulloch T, Esler CP, Shaw JA, Ashford RU, Royle NJ (2020) The circulating nucleic acid characteristics of non-metastatic soft tissue sarcoma patients. Int J Mol Sci. https://doi.org/10.3390/ijms21124483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21124483</ArticleId>
            <ArticleId IdType="pubmed">32599895</ArticleId>
            <ArticleId IdType="pmc">7349923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD (2018) Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group. Br J Cancer 119:615–621. https://doi.org/10.1038/s41416-018-0212-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-018-0212-9</ArticleId>
            <ArticleId IdType="pubmed">30131550</ArticleId>
            <ArticleId IdType="pmc">6162271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>George SL, Izquierdo E, Campbell J, Koutroumanidou E, Proszek P, Jamal S, Hughes D, Yuan L, Marshall LV, Carceller F, Chisholm JC, Vaidya S, Mandeville H, Angelini P, Wasti A, Bexelius T, Thway K, Gatz SA, Clarke M, Al-Lazikani B, Barone G, Anderson J, Tweddle DA, Gonzalez D, Walker BA, Barton J, Depani S, Eze J, Ahmed SW, Moreno L, Pearson A, Shipley J, Jones C, Hargrave D, Jacques TS, Hubank M, Chesler L (2019) A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. Eur J Cancer 121:224–235. https://doi.org/10.1016/j.ejca.2019.07.027</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.07.027</ArticleId>
            <ArticleId IdType="pubmed">31543384</ArticleId>
            <ArticleId IdType="pmc">6839402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemming ML, Klega KS, Rhoades J, Ha G, Acker KE, Andersen JL, Thai E, Nag A, Thorner AR, Raut CP, George S, Crompton BD (2019) Detection of circulating tumor DNA in patients with leiomyosarcoma with progressive disease. JCO Precis Oncol. https://doi.org/10.1200/po.18.00235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/po.18.00235</ArticleId>
            <ArticleId IdType="pubmed">30793095</ArticleId>
            <ArticleId IdType="pmc">6380497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutteridge A, Rathbone VM, Gibbons R, Bi M, Archard N, Davies KEJ, Brown J, Plagnol V, Pillay N, Amary F, O’Donnell P, Gupta M, Tirabosco R, Flanagan AM, Forshew T (2017) Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Med 6:2194–2202. https://doi.org/10.1002/cam4.1146</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1146</ArticleId>
            <ArticleId IdType="pubmed">28834325</ArticleId>
            <ArticleId IdType="pmc">5633548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klega K, Imamovic-Tuco A, Ha G, Clapp AN, Meyer S, Ward A, Clinton C, Nag A, Van Allen E, Mullen E, DuBois SG, Janeway K, Meyerson M, Thorner AR, Crompton BD (2018) Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors. JCO Precis Oncol. https://doi.org/10.1200/po.17.00285</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/po.17.00285</ArticleId>
            <ArticleId IdType="pubmed">30027144</ArticleId>
            <ArticleId IdType="pmc">6049092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prudner BC, Ball T, Rathore R, Hirbe AC (2020) Diagnosis and management of malignant peripheral nerve sheath tumors: current practice and future perspectives. Neurooncol Adv 2:i40–i49. https://doi.org/10.1093/noajnl/vdz047</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/noajnl/vdz047</ArticleId>
            <ArticleId IdType="pubmed">32642731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urban T, Lim R, Merker VL, Muzikansky A, Harris GJ, Kassarjian A, Bredella MA, Plotkin SR (2014) Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med 39:e301-307. https://doi.org/10.1097/RLU.0b013e3182a757d3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RLU.0b013e3182a757d3</ArticleId>
            <ArticleId IdType="pubmed">24152623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, Tsokos M, Salzer W, Gillespie A, Baldwin A, Derdak J, Widemann B (2013) 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer 60:59–64. https://doi.org/10.1002/pbc.24212</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.24212</ArticleId>
            <ArticleId IdType="pubmed">22645095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM (2019) Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology 93:e1076</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller DT, Cortes-Ciriano I, Pillay N, Hirbe AC, Snuderl M, Bui MM, Piculell K, Al-Ibraheemi A, Dickson BC, Hart J, Jones K, Jordan JT, Kim RH, Lindsay D, Nishida Y, Ullrich NJ, Wang X, Park PJ, Flanagan AM (2020) Genomics of MPNST (GeM) consortium: rationale and study design for multi-omic characterization of NF1-associated and sporadic MPNSTs. Genes. https://doi.org/10.3390/genes11040387</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/genes11040387</ArticleId>
            <ArticleId IdType="pubmed">33374416</ArticleId>
            <ArticleId IdType="pmc">7824201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE (2017) Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aan2415</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aan2415</ArticleId>
            <ArticleId IdType="pubmed">28814544</ArticleId>
            <ArticleId IdType="pmc">6714979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts H, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446–451. https://doi.org/10.1038/nature22364</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22364</ArticleId>
            <ArticleId IdType="pubmed">28445469</ArticleId>
            <ArticleId IdType="pmc">5812436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892. https://doi.org/10.1056/NEJMoa1113205</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1113205</ArticleId>
            <ArticleId IdType="pubmed">22397650</ArticleId>
            <ArticleId IdType="pmc">22397650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knuever J, Weiss J, Persa OD, Kreuzer K, Mauch C, Hallek M, Schlaak M (2020) The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. Sci Rep 10:4940. https://doi.org/10.1038/s41598-020-61818-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-61818-1</ArticleId>
            <ArticleId IdType="pubmed">32188904</ArticleId>
            <ArticleId IdType="pmc">7080785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forschner A, Weißgraeber S, Hadaschik D, Schulze M, Kopp M, Kelkenberg S, Sinnberg T, Garbe C, Biskup S, Battke F (2020) Circulating tumor DNA correlates with outcome in metastatic melanoma treated by BRAF and MEK inhibitors—results of a prospective biomarker study. Onco Targets Ther 13:5017–5032. https://doi.org/10.2147/ott.S248237</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/ott.S248237</ArticleId>
            <ArticleId IdType="pubmed">32581559</ArticleId>
            <ArticleId IdType="pmc">7280255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, Smith N, Villa S, Dransfield J, Clipson A, White D, Nessa K, Ferdous S, Howell M, Gupta A, Kilerci B, Mohan S, Frese K, Gulati S, Miller C, Jordan A, Eaton H, Hickson N, O’Brien C, Graham D, Kelly C, Aruketty S, Metcalf R, Chiramel J, Tinsley N, Vickers AJ, Kurup R, Frost H, Stevenson J, Southam S, Landers D, Wallace A, Marais R, Hughes AM, Brady G, Dive C, Krebs MG (2019) Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med 25:738–743. https://doi.org/10.1038/s41591-019-0380-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0380-z</ArticleId>
            <ArticleId IdType="pubmed">31011204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. https://doi.org/10.1038/s41591-020-1063-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-1063-5</ArticleId>
            <ArticleId IdType="pubmed">33020649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC (2018) Circulating tumor DNA analysis in patients with cancer: American Society of clinical oncology and college of American pathologists joint review. J Clin Oncol 36:1631–1641. https://doi.org/10.1200/jco.2017.76.8671</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2017.76.8671</ArticleId>
            <ArticleId IdType="pubmed">29504847</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
